JPMorgan raises Ascendis Pharma target to $167, keeps Overweight
JPMorgan analyst Jessica Fye adjusted the price target for Ascendis Pharma (NASDAQ:ASND), a $7.74 billion biotech company, to $167.00, a slight increase from the previous $165.00, while reiterating ...
J.P. Morgan Sticks to Their Buy Rating for Ascendis Pharma (ASND)
J.P. Morgan analyst Jessica Fye maintained a Buy rating on Ascendis Pharma (ASND – Research Report) today and set a price target of $167.00.
J.P. Morgan Remains a Buy on Intra-Cellular Therapies (ITCI)
In a report released on January 27, Jessica Fye from J.P. Morgan maintained a Buy rating on Intra-Cellular Therapies (ITCI – Research Report), ...